Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-181d-5p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Not available
Cancer name
Ovarian Cancer
Cancer site
qRT-PCR,Western blot,Dual-luciferase assay
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
these findings suggest that miR-181d-mediated OGT inhibition restricts the glycosylation of KEAP1, and then reduces the ubiquitination and degradation of NRF2, leading to DDP resistance of OC
Tissue resource
ovarian cancer tumor tissues
ovarian cancer cell lines A2780
ovarian cancer cisplatin-resistant cell lines A2780/DDP
human embryonic kidney cell lines 293T
Experiment
None
Institute
Hunan Provincial People's Hospital and Hunan Provincial Maternal and Child Healthcare Hospital
shanghai Meixuan Biological Science and Technology Ltd
American Type Culture Collection
Country
China
China
United States
Continent
Asia
Asia
North Amercian
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.